Organ-specific toxicity of romidepsin in patients with preexisting cardiovascular disease: a retrospective analysis
- 11 March 2022
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (8) , 1989-1992
Abstract
Mycosis fungoides (MF), the most common form of cutaneous T cell lymphoma (CTCL), is primarily an indolent disease [1,2]. However, advanced stages of MF and Sezary syndrome (SS) may involve the blo...Keywords
This publication has 10 references indexed in Scilit:
- Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2020
- An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphomaJournal of Dermatological Treatment, 2017
- Romidepsin Therapy Over 5 Years in a Clinical Setting—Real-world ExperienceJAMA Oncology, 2016
- Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaBiomarker Research, 2014
- Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP ChannelClinical Cancer Research, 2013
- A Focus on the Preclinical Development and Clinical Status of the Histone Deacetylase Inhibitor, Romidepsin (Depsipeptide, Istodax®)Epigenomics, 2012
- Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.Blood, 2009
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood, 2004
- A phase I trial of Depsipeptide (FR901228) in patients with advanced cancerJournal of Experimental Therapeutics and Oncology, 2002